“The past quarter was marked by a number of critical advancements on both the clinical and corporate sides of our business. We are in the final stages of preparation for the launch of our Phase 2a biomarker study, which is expected this year. This study will evaluate our lead program, GRI-0621 for the treatment of IPF, an Orphan indication in need of innovative solutions. We are also finalizing our IND-enabling studies for our SLE program with the goal of filing an IND in the first half of 2024,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “On the corporate side, we closed our merger and began trading on the Nasdaq under the ticker ‘GRI,’ which we believe sets the stage for the future success of the Company. We also refreshed our corporate identity and launched a new corporate website, which is in line with our mission going forward and provides all key stakeholders a reliable source to access information and updates on the Company,” continued Dr. Hertz.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRI:
- GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- GRI Bio presents preclinical data on GRI-0803
- GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
- GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series